Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2030

Conditions
NMOSD
Interventions
DRUG

Rituximab (R)

1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months

DRUG

Eculizumab (Soliris®)

900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks

DRUG

Ravulizumab

"* 40 to \< 60 kg: 2400 mg~* 60 to \< 100 kg: 2700 mg~* 100 kg: 3000 mg as an induction dose, followed by~* 40 to \< 60 kg: 3000 mg~* 60 to \< 100 kg: 3300 mg~* 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose"

DRUG

Satralizumab

120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks

DRUG

Inebilizumab

300 mg on Day 1 and Day 15, followed by 300 mg every 6 months

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Unknown

Charité - Universitätsmedizin Berlin, Berlin

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

The Sumaira Foundation

UNKNOWN

lead

Massachusetts General Hospital

OTHER